



Research and Development

In accordance with our “Patients first” corporate philosophy, Sawai is applying advanced technological capabilities to develop pharmaceuticals chosen by healthcare professionals, patients and distributors.

Sawai leads the Japanese generics industry in R&D investment to develop high value-added new products.

Sawai conducts in-house research to further improve quality and create high value-added products. With regard to raw materials, we minutely analyze purity, properties and other factors and carefully select from sources around the world only materials that correspond to rigorous internal standards.

In October 2009, we opened the Pharmaceutical Technology Center, which has contributed further innovation in drug formulation and enhanced our framework for increasing product value by using the latest formulation technologies and production technologies to add modifications and refinements not only to newly developed products, but also to existing products as well. The center will further accelerate drug formulation research with the aim of achieving “Ever-superior quality”: Sawai Group’s commitment to continuous improvement, including active ingredient purity, tablet formulation devices and information services.

To accomplish these R&D goals, the Company ac-

tively invests in R&D. Our R&D expenses of ¥3,902 million are the highest among generics manufacturers in Japan.

The size of the market for products whose patents are expected to expire from fiscal 2011 through fiscal 2015 is expected to reach approximately ¥1,470.0 billion, and competition is likely to further intensify, fueled by expectation that these products will be replaced by generics.

As the industry leader, Sawai will continue to put the interest of patients first by offering the industry’s premier lineup of new products made possible by the development and successful introduction of high-quality, high value-added formulations and by refining existing products. We will also consider product development in the field of anticancer drugs, where tremendous market expansion is expected to continue, and biosimilars development with a focus on antibody drugs.

Major Products

Trade Name	Active Ingredient	Dosage Form	Strength
HALTHROW OD	Tamsulosin Hydrochloride	Oral Disintegrating Tablets	0.2mg
LIMARMONE	Limaprost Alfadex	Tablets	5µg
PRAVATIN	Pravastatin Sodium	Tablets	10mg
AMLODIPINE	Amlodipine Besilate	Tablets	5mg
LASOPRAN OD	Lansoprazole	Oral Disintegrating Tablets	15mg
VOGLIBOSE OD	Voglibose	Oral Disintegrating Tablets	0.3mg
EPINAZION	Epinastine Hydrochloride	Tablets	20mg
LIPODOWN	Simvastatin	Tablets	5mg
REBAMIPIDE	Rebamipide	Tablets	100mg
CLARITHROMYCIN	Clarithromycin	Tablets	200mg (potency)
ARTIONE	Carvedilol	Tablets	10mg
SEFTAC	Teprenone	Capsules	50mg
OMEPRAZOLE	Omeprazole	Tablets	20mg
ETHYL ICOSAPENTATE	Ethyl Icosapentate	Seamless Capsules	900mg
METHYCOOL	Mecobalamin	Tablets	500µg
FAMOTIDINE	Famotidine	Tablets	20mg
CILNIDIPINE	Cilnidipine	Tablets	10mg
BEZATATE	Bezafibrate	Tablets	200mg
ITORAT	Itraconazole	Capsules	50mg
UBIRON	Ursodeoxycholic Acid	Tablets	100mg

Major New Products Listed in Nov. 2010 - June 2011

Trade Name	Active Ingredient	Dosage Form	Strength
RABEPRAZOLE Na	Sodium Rabeprazole	Tablets	10mg/20mg
GLIMEPIRIDE	Glimepiride	Tablets	1mg/3mg
FLUVOXAMINE MALEATE	Fluvoxamine Maleate	Tablets	25mg/50mg/75mg
POLAPREZINC OD	Polaprezinc	Tablets	75mg
NICARPINE	Nicardipine Hydrochloride	Injections	25mg/25mL/1ampule
ALLOZYM	Allopurinol	Tablets	50mg
EDARAVONE	Edaravone	Injections	30mg/20mL/1ampule 30mg/100mL/bag
TAMOXIFEN	Tamoxifen Citrate	Tablets	30.4mg
ARDEPHYLLIN	Theophylline	Tablets	50mg/200mg
SIMVASTATIN	Simvastatin	Tablets	20mg
CEFTAZIDIME	Ceftazidime	Injections	0.5g (potency)/1 vial
FLUCONAZOLE	Fluconazole	Injections	50mg/1 vial



RABEPRAZOLE Na tablets




AMLODIPINE OD tablets



HALTHROW OD tablets

Sales by Therapeutic Category (%)



Representative Sawai Pharmaceutical Value-added Innovations

Easy-to-administer, enhanced drugs

Capsules in tablet form	Large, hard-to-swallow capsules made into tablet form
Miniaturized tablets	Miniaturization of large, hard-to-swallow tablets
Improved taste	Sugar and film coatings to mask bitter taste

Enhancements that facilitate prescription and dispensing for healthcare providers

Easy to split	Tablets with cut lines that make them easy to split
Improved safety	Improved safety against humidity, temperature, sunlight and other conditions

Safety improvements linked to reducing medical errors

Better containers	New, high-safety containers that protect against breakage
Pre-filled syringes	Switch to syringes with solution filled in advance
Clear displays	Clear descriptions of drug names, standards and effects included in packaging